TRCT
TWST icon

Tower Research Capital (TRC)’s Twist Bioscience TWST Stock Holding History

Tower Research Capital (TRC)’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Sell
2,650
-6,332
-70% -$412K 0.01% 1461
2026
Q1 		$427K Buy
8,982
+8,485
+1,707% +$380K 0.01% 1026
2025
Q4 		$15.8K Sell
497
-33,790
-99% -$1.05M ﹤0.01% 3276
2025
Q3 		$965K Buy
34,287
+16,112
+89% +$488K 0.03% 522
2025
Q2 		$669K Sell
18,175
-1,042
-5% -$36K 0.02% 763
2025
Q1 		$754K Buy
19,217
+13,158
+217% +$593K 0.02% 630
2024
Q4 		$282K Buy
6,059
+1,414
+30% +$63.9K 0.01% 1455
2024
Q3 		$210K Sell
4,645
-3,905
-46% -$186K 0.01% 1584
2024
Q2 		$421K Buy
8,550
+5,948
+229% +$243K 0.01% 1478
2024
Q1 		$89.3K Sell
2,602
-272
-9% -$9.82K ﹤0.01% 1883
2023
Q4 		$106K Sell
2,874
-3,103
-52% -$71.8K ﹤0.01% 2608
2023
Q3 		$121K Sell
5,977
-3,253
-35% -$71.5K ﹤0.01% 1842
2023
Q2 		$189K Sell
9,230
-4,142
-31% -$62K 0.01% 1596
2023
Q1 		$202K Buy
13,372
+8,635
+182% +$191K 0.01% 1367
2022
Q4 		$113K Sell
4,737
-28,699
-86% -$832K ﹤0.01% 1743
2022
Q3 		$1.18M Buy
33,436
+27,424
+456% +$1.16M 0.02% 632
2022
Q2 		$210K Buy
6,012
+4,689
+354% +$166K ﹤0.01% 1741
2022
Q1 		$65K Sell
1,323
-1,642
-55% -$91K ﹤0.01% 2532
2021
Q4 		$230K Buy
2,965
+2,643
+821% +$271K ﹤0.01% 1648
2021
Q3 		$34K Sell
322
-5,479
-94% -$627K ﹤0.01% 3270
2021
Q2 		$773K Sell
5,801
-23,820
-80% -$2.77M 0.02% 839
2021
Q1 		$3.67M Buy
29,621
+14,178
+92% +$2.15M 0.06% 289
2020
Q4 		$2.18M Buy
15,443
+13,909
+907% +$1.54M 0.07% 202
2020
Q3 		$117K Sell
1,534
-6,630
-81% -$413K ﹤0.01% 3032
2020
Q2 		$370K Buy
+8,164
New +$293K 0.02% 1270
2019
Q4 		– Sell
-395
Closed -$9K – 4377
2019
Q3 		$9K Sell
395
-1,089
-73% -$31.7K ﹤0.01% 3017
2019
Q2 		$43K Buy
1,484
+1,251
+537% +$33.1K ﹤0.01% 1683
2019
Q1 		$5K Sell
233
-2,791
-92% -$63.1K ﹤0.01% 3099
2018
Q4 		$70K Buy
+3,024
New +$67K 0.01% 1126

Other funds holding TWST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Tower Research Capital (TRC)'s TWST Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Twist Bioscience (TWST) stake by 70% in Q2 2026, selling an estimated $412K and leaving 2,650 shares worth $273K. The position accounts for 0.01% of the portfolio, ranked #1461.

Tower Research Capital (TRC) first reported a position in TWST in Q4 2018 and has held it in 29 quarters since. The position peaked at $3.67M in Q1 2021. 337 funds tracked by Wall St. Rank hold TWST as of Q2 2026.

  • Tower Research Capital (TRC) held 2,650 shares of Twist Bioscience worth $273K as of Q2 2026.
  • Tower Research Capital (TRC) sold 6,332 Twist Bioscience shares in Q2 2026, an estimated $412K.
  • Twist Bioscience made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1461 holding.
  • Tower Research Capital (TRC) first reported a position in Twist Bioscience in Q4 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Twist Bioscience position peaked at $3.67M in Q1 2021.
  • 337 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.